JP5847588B2 - 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 - Google Patents

磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 Download PDF

Info

Publication number
JP5847588B2
JP5847588B2 JP2011550316A JP2011550316A JP5847588B2 JP 5847588 B2 JP5847588 B2 JP 5847588B2 JP 2011550316 A JP2011550316 A JP 2011550316A JP 2011550316 A JP2011550316 A JP 2011550316A JP 5847588 B2 JP5847588 B2 JP 5847588B2
Authority
JP
Japan
Prior art keywords
lipid
nanoparticle
dtpa
nanoparticles
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011550316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518012A5 (enExample
JP2012518012A (ja
Inventor
ホ、ロドニー・ジェイ．ワイ．
ヘクマン、ジョン・デー．
マラビラ、ケン
Original Assignee
ユニヴァーシティ オブ ワシントン
ユニヴァーシティ オブ ワシントン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オブ ワシントン, ユニヴァーシティ オブ ワシントン filed Critical ユニヴァーシティ オブ ワシントン
Publication of JP2012518012A publication Critical patent/JP2012518012A/ja
Publication of JP2012518012A5 publication Critical patent/JP2012518012A5/ja
Application granted granted Critical
Publication of JP5847588B2 publication Critical patent/JP5847588B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2011550316A 2009-02-13 2010-02-16 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 Active JP5847588B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15245909P 2009-02-13 2009-02-13
US61/152,459 2009-02-13
US16298909P 2009-03-24 2009-03-24
US61/162,989 2009-03-24
PCT/US2010/024324 WO2010094043A2 (en) 2009-02-13 2010-02-16 Gadolinium expressed lipid nanoparticles for magnetic resonance imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015229868A Division JP6072205B2 (ja) 2009-02-13 2015-11-25 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子

Publications (3)

Publication Number Publication Date
JP2012518012A JP2012518012A (ja) 2012-08-09
JP2012518012A5 JP2012518012A5 (enExample) 2013-04-04
JP5847588B2 true JP5847588B2 (ja) 2016-01-27

Family

ID=42562321

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011550316A Active JP5847588B2 (ja) 2009-02-13 2010-02-16 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子
JP2015229868A Active JP6072205B2 (ja) 2009-02-13 2015-11-25 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015229868A Active JP6072205B2 (ja) 2009-02-13 2015-11-25 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子

Country Status (5)

Country Link
US (2) US20120087857A1 (enExample)
EP (1) EP2398503B1 (enExample)
JP (2) JP5847588B2 (enExample)
CN (2) CN102341126A (enExample)
WO (1) WO2010094043A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833926A4 (en) * 2012-04-05 2015-11-25 Univ Florida NEUROPHILIC NANOPARTICLES
GB2549861A (en) * 2014-11-03 2017-11-01 Albert Einstein College Medicine Inc Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
CN107708672A (zh) * 2015-06-15 2018-02-16 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
CN107412790B (zh) * 2017-09-08 2019-02-22 丽水市中心医院 一种核磁共振纳米材料的制备方法
US12226496B2 (en) 2018-04-30 2025-02-18 Bar-Ilan University Polymeric core-shell particles
WO2020154623A1 (en) * 2019-01-24 2020-07-30 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
US11116854B2 (en) * 2020-01-29 2021-09-14 Texas Children's Hospital Targeted contrast agents for MRI of amyloid deposition
CN113730614B (zh) * 2021-09-09 2022-02-22 南京市第一医院 一种镥标记的纳米载体及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833948A (en) * 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
EP1105162A1 (en) * 1998-08-10 2001-06-13 Bracco Research S.A. Combination of a positive mri contrast agent with a negative mri contrast agent
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7514098B2 (en) * 2001-05-30 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Use of targeted cross-linked nanoparticles for in vivo gene delivery
US7459145B2 (en) * 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
EP1648299A4 (en) * 2003-07-09 2008-10-22 California Pacific Med Center REMOTE DETERMINATION OF THE DELIVERY OF SUBSTANCES IN CELLS
ES2531751T3 (es) 2003-12-22 2015-03-18 Bracco Suisse Sa Montaje de microvesícula rellena de gas con componente activo para imagenología de contraste
US20050265922A1 (en) * 2004-04-20 2005-12-01 Emory University Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
US20090238767A1 (en) * 2004-12-17 2009-09-24 Koninklijke Philips Electronics, N.V. Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
CA2680206C (en) * 2007-03-05 2015-07-07 Washington University Nanoparticle delivery systems for membrane-integrating peptides
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
WO2009110939A2 (en) * 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation

Also Published As

Publication number Publication date
WO2010094043A2 (en) 2010-08-19
US20120087857A1 (en) 2012-04-12
EP2398503B1 (en) 2018-10-31
CN102341126A (zh) 2012-02-01
JP2016094425A (ja) 2016-05-26
US20170173190A1 (en) 2017-06-22
CN106362171A (zh) 2017-02-01
JP2012518012A (ja) 2012-08-09
EP2398503A4 (en) 2015-05-06
EP2398503A2 (en) 2011-12-28
JP6072205B2 (ja) 2017-02-01
US11207430B2 (en) 2021-12-28
WO2010094043A3 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
JP6072205B2 (ja) 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子
Corbin et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents
Sandiford et al. Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging
Okuhata Delivery of diagnostic agents for magnetic resonance imaging
Aryal et al. Engineered magnetic hybrid nanoparticles with enhanced relaxivity for tumor imaging
Krause et al. Dendrimers in diagnostics
Kiessling et al. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging
MXPA97002523A (en) Agents liposomi
Trubetskoy et al. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes
JP2014526442A (ja) アポトーシス−ターゲティングナノ粒子
Tan et al. Synthesis and evaluation of nanoglobular macrocyclic Mn (II) chelate conjugates as non-gadolinium (III) MRI contrast agents
US6468505B1 (en) Technique to monitor drug delivery noninvasively in vivo
JP2012518012A5 (enExample)
Chen et al. Peptide-functionalized NaGdF 4 nanoparticles for tumor-targeted magnetic resonance imaging and effective therapy
Mulas et al. Mn (II)-Based Lipidic Nanovesicles as High-Efficiency MRI Probes
Yan et al. Research progress of magnetic resonance imaging contrast agents
JP6852080B2 (ja) 混合シクロデキストリン種を担持するポリロタキサン、およびその使用
Huang et al. Gadolinium-conjugated star-block copolymer polylysine-modified polyethylenimine as high-performance T 1 MR imaging blood pool contrast agents
Torchilin et al. Liposomes and micelles to target the blood pool for imaging purposes
Karathanasis et al. MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in ratglioma
US20140363378A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments
US20220105207A1 (en) Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of Cancer
KR20120045690A (ko) 최적의 글루콘산 도입으로 향상된 생체 적용능을 확보한 글루콘산과 비고분자 생체 존재물질이 표면개질제로 도입된 산화철 나노입자 및 이를 포함한 암 진단 및 치료용 조성물
KR20020089494A (ko) 금속 이온 킬레이트 착물이 포합된 담즙산 유도체의미세혈관 투과성 진단 평가를 위한 용도
WO2016022987A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151125

R150 Certificate of patent or registration of utility model

Ref document number: 5847588

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250